Today we are excited to announce the merger of NDA Group and SSI Strategy, creating an an industry leading life sciences consulting firm. This collaboration combines two trusted consultancies to provide end-to-end support for drug development companies, guiding them from concept to commercialization.
SSI Strategy brings exceptional medical, clinical, and development expertise to complement our existing regulatory capabilities. Their teams, comprising former Chief Medical Officers, Heads of Medical Affairs, Clinical Development, and Safety, along with seasoned business consultants, perfectly align with our network of 100+ ex-regulators and industry experts.
By leveraging our combined strengths, we can offer solutions covering the entire product life cycle. From expediting clinical development strategies to navigating complex regulatory pathways and maximizing real-world evidence, we will help clients overcome obstacles and achieve their goals more efficiently.
For drug developers, this merger means access to a single partner that fulfils all your requirements. No more gaps – just tailored solutions that enhance the value of your assets from start to finish.
For NDA Group, this merger with SSI Strategy realizes our vision of becoming a comprehensive life sciences consultancy guiding product development from inception to launch.
To discover more about the benefits of this merger, please refer to our official press release. If you have any questions, feel free to reach out to us.
We eagerly anticipate collaborating as a united team and driving success together!